Publicacións en colaboración con investigadores/as de Centro Nacional de Epidemiología (29)

2024

  1. Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters

    International Journal of Antimicrobial Agents, Vol. 63, Núm. 1

2022

  1. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

  2. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

  3. Progress in the quality of care for newly diagnosed people with HIV in Spain (2004–2019)

    Antiviral Therapy, Vol. 27, Núm. 4

  4. Temporal Trends and Geographic Variability in the Prescription of Antiretroviral Treatments in People Living with HIV in Spain, 2004–2020

    Journal of Clinical Medicine, Vol. 11, Núm. 7

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  2. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study

    The Lancet Infectious Diseases, Vol. 21, Núm. 6, pp. 783-792

  3. Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinson’s disease

    BMC Neurology, Vol. 21, Núm. 1

  4. Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort

    Clinical Microbiology and Infection, Vol. 27, Núm. 11, pp. 1678-1684

  5. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

    Clinical Microbiology and Infection, Vol. 27, Núm. 2, pp. 244-252

2020

  1. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain

    Clinical Microbiology and Infection, Vol. 26, Núm. 11, pp. 1525-1536

  2. Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: A multicentre cohort study

    AIDS Research and Therapy, Vol. 17, Núm. 1

  3. Effects of Motor Symptom Laterality on Clinical Manifestations and Quality of Life in Parkinson's Disease

    Journal of Parkinson's Disease, Vol. 10, Núm. 4, pp. 1611-1620

  4. Non-motor symptom burden in patients with Parkinson’s disease with impulse control disorders and compulsive behaviours: results from the COPPADIS cohort

    Scientific Reports, Vol. 10, Núm. 1

  5. The impact of freezing of gait on functional dependency in Parkinson’s disease with regard to motor phenotype

    Neurological Sciences, Vol. 41, Núm. 10, pp. 2883-2892

2019

  1. COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015): an ongoing global Parkinson's disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation

    European Journal of Neurology, Vol. 26, Núm. 11, pp. 1399-1407

  2. High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinson’s disease patients

    Journal of Neural Transmission, Vol. 126, Núm. 12, pp. 1599-1608

2018

  1. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

  2. Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment

    Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337

2017

  1. FIRST CASES OF SEVERE FLACCID PARALYSIS ASSOCIATED WITH ENTEROVIRUS D68 INFECTION IN SPAIN, 2015–2016

    Pediatric Infectious Disease Journal, Vol. 36, Núm. 12, pp. 1214-1216